You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Urinary Biomarkers of Renal Mitochondrial Dysfunction
SBC: SCHNELLGEN, INC. Topic: NIEHSDESCRIPTION (provided by applicant): The long-term goal of this project is to identify and validate biomarkers of mitochondrial dysfunction due to environmental stressors. Diverse acute insults from surgery, trauma, ischemia/reperfusion (I/R) and drug andenvironmental chemical toxicity lead to mitochondrial dysfunction and result in cell injury and death in many organs/tissues (e.g. heart, lung, b ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Nogo Decoy Receptor Therapy for the Treatment of Glaucoma
SBC: RENETX BIO, INC. Topic: NIMHDDESCRIPTION (provided by applicant): The objective of this phase I STTR application is to continue assessment of the relevance and feasibility of Nogo decoy receptor therapy for the treatment of glaucoma. The secondary objective is to obtain pharmacokinetic data important for designing additional preclinical efficacy studies and formulating a drug development plan for glaucoma. Our long term objec ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Antimicrobial Foley Catheter to Prevent CAUTIs
SBC: HYDROMER, INC. Topic: NIDDKDESCRIPTION (provided by applicant): Catheter-associated urinary tract infections (CAUTI) are a leading cause of hospital-acquired infections and lead to increased costs, suffering and mortality. A primary contributor to CAUTI is formation of bacterial biofilms on indwelling catheters. Biofilms are inherently resistant to most antibiotics, and once established serve as a bacterial reservoir propag ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Use of EF2K Inhibitors to Reduce Toxicity to Normal Tissues in Chemotherapy
SBC: LONGEVICA PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION (provided by applicant): Eukaryotic elongation factor 2 protein kinase (eEF2K) is a ubiquitously expressed protein that belongs to a family of alpha kinases characterized by an atypical kinase domain. Our recent findings demonstrate that inhibition or genetic inactivation of eEF2K protects normal tissues from cytotoxic effects of chemotherapeutic agents and ionizing radiation. We hav ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Functional-selection of affinity reagents against DNA-protein complexes using targeted chromatin sequences
SBC: AXIOMX INC Topic: NIDDKDESCRIPTION (provided by applicant): Site-specific binding of proteins to DNA plays an important role in cell development, cell signaling, the cell cycle, and diseases such as cancer. There are two overarching goals to this proposal: (1) to develop a meansfor the identification of proteins bound to specific DNA sequences, and (2) to develop a better method for the identification of immunoprecipita ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Reversal of Myocardial Infarction by Localized Stimulation
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTION (provided by applicant): Heart attacks (i.e. myocardial infarction or MI) occur in more than 1.2 million patients annually. Advances in pharmacological therapy have dramatically improved survival following the initial MI. Consequently, the number of patients with previous MI continues to increase, and as a result, put in jeopardy millions of patients for development of heart failure. I ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health